Veracyte (VCYT) Capital Expenditures (2012 - 2026)

Veracyte (VCYT) has 15 years of Capital Expenditures data on file, last reported at $3.0 million in Q1 2026.

• Quarterly Capital Expenditures rose 62.84% year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 million (up 175.86% YoY) and the FY2025 annual result came in at $2.3 million, up 94.6% from the prior year.
• Capital Expenditures grew to $3.0 million in Q1 2026 per VCYT's latest filing, from $1.5 million in the prior quarter.
• The five-year high for Capital Expenditures was $9.5 million in Q4 2023, with the low at -$6.0 million in Q4 2024.
• Average Capital Expenditures over 5 years is $1.5 million, with a median of $1.8 million recorded in 2025.
• Year-over-year, Capital Expenditures jumped 418.56% in 2022 and sank 347.26% in 2023.
• Veracyte's Capital Expenditures stood at $1.9 million in 2022, then soared by 409.46% to $9.5 million in 2023, then tumbled by 162.49% to -$6.0 million in 2024, then soared by 124.83% to $1.5 million in 2025, then jumped by 100.14% to $3.0 million in 2026.
• Business Quant data shows VCYT's Capital Expenditures at $3.0 million in Q1 2026, $1.5 million in Q4 2025, and $323000.0 in Q3 2025.